Sandoz Sandoz completes $170M buy of Lucentis biosimilar from Coherus BioSciences

2024-03-04

上市批准并购生物类似药

Sandoz’s $170 million cash deal to buy ophthalmology biosimilar Cimerli from Coherus BioSciences has completed early following its announcement in January. The deal, which is the first for Sandoz since spinning off from Novartis, includes a biologics license application, product inventory and ophthalmology sales, according to Sandoz . Cimerli, a copycat version of Roche’s eye disease drug Lucentis, brought in $40 million in the third quarter of 2023, a 50% increase compared to the prior quarter, according to Coherus’ latest earnings report . The biosimilar, an anti-VEGF therapy, won approval in August 2022. It is the only approved ranibizumab biosimilar to Roche’s Lucentis injection covering the same five eye conditions: wet AMD AMD, diabetic retinopathy, diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构